lulizumab pegol

Ligand id: 8460

Name: lulizumab pegol

Compound class Antibody
Ligand families/groups Immune checkpoint modulators
International Nonproprietary Names
INN number INN
9940 lulizumab pegol
BMS-931699 | BMS931699
Lulizumab pegol is a humanised PEGylated anti-CD28 antibody-based biologic, developed as a potential treatment for autoimmune diseases. This so-called domain antibody (dAb) contains the smallest functional binding unit and lacks the divalent structure characteristic of a complete antibody [3]. PEGylation improves solubility and extends circulating half-life [2].
Peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Database Links
Specialist databases
IMGT/mAb-DB 499
Other databases
GtoPdb PubChem SID 252166670
Search PubMed clinical trials lulizumab pegol
Search PubMed titles lulizumab pegol
Search PubMed titles/abstracts lulizumab pegol
Wikipedia Lulizumab_pegol